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165the use of both technologies during PCI, however, and when using
IVUS, operators often intervene based on an IVUS minimum
lumen area (MLA) of <4.0 mm2 (4).
The main objective of the FIRST (Fractional Flow Reserve and
Intravascular Ultrasound Relationship) study was to determine the
optimal MLA by IVUS that correlated with FFR. We found that
anatomic measurements by IVUS showed a moderate correlation
with the FFR values, and the optimal cutoff varied from 2.4 mm2
to 3.6 mm2 based on vessel size (1). IVUS MLA measurements are
better correlated to FFR in large, proximal vessels, and in left
anterior lesions, which are known to perfuse to a larger myocardial
distribution. This actually supports the notion that IVUS MLA, if
used wisely, can assist in the differentiation of lesion severity and its
hemodynamic signiﬁcance. For example, there is probably no
reason to perform either FFR or IVUS MLA measurements in
small vessels <2.25 mm and in the nondominant left circumﬂex. In
the FIRST study, over 90% of the FFR measurements in the left
circumﬂex were >0.80.
The literature has recognized the limitations of FFR in patients
with left main disease post-myocardial infarction, in addition to
reproducibility of the results and its dependency in adenosine
infusion. Further, the landmark studies that have determined the
routine use of FFR for intermediate lesions, including DEFER and
FAME 1 and 2, all had signiﬁcant limitations and are not current
regarding the use of second-generation drug-eluting stents. The
1 question not addressed in the FIRST study is whether the accu-
racy level of IVUS MLA is sufﬁcient for routine implementation of
these measurements into clinical practice. The only way to address
this issue is to conduct a prospective, clinical randomized trial.
Dr. De Caterina and colleagues surprisingly oppose a FAME-
like trial design with the use of IVUS MLA cutoff indices for
intervention decisions. Is the rationale for this resistance related to
the strong conviction in the power of FFR as the ultimate tool, or is
it related to the fear that IVUS MLA-guided PCI will show similar
superiority to angiography-guided PCI? Perhaps an optimal study
design would be to add an FFR arm, which will allow us to examine
the best treatment strategy for our patients undergoing routine
PCI: IVUS or FFR. As Andreas Grüntzig used to say, “If in doubt,
let’s randomize.”*Ron Waksman, MD
Rebecca Torguson, MPH
Jacek Legutko, MD
*MedStar Washington Hospital Center
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Circulation 1999;100:256–61.Fluid Re-Distribution Rather Than
Accumulation Causes Most Cases
of Decompensated Heart Failure
Dr. Gheorghiade and colleagues’ recent review (1) pertaining to
re-hospitalization for heart failure (HF) is based largely upon the
disputed assumption that increases in total body salt and water
underlie the congestive presentation. Mounting evidence suggests
that this assumption is likely incorrect for most patients, and may
explain the failure ofmultiple drugs and devices targeting reduction of
total body salt and water to reduce rehospitalization risk and HF
mortality. For accumulation of total body salt and water to be the
basis of worsening HF, increases in weight would necessarily be
evident early in the course leading up to a hospitalization for HF
(HHF). Studies instead have documented that the majority of
patients gain little or no weight before HHF (2–4), despite the fact
that ﬁlling pressures rise signiﬁcantly (4). Furthermore, when weight
gain occurs, it does so shortly before HHF (2), long after ﬁlling
pressures have begun to rise. Although Dr. Gheorghiade et al. (5)
have previously acknowledged this lack of evidence for weight gain
before HHF, their current review has ignored this “inconvenient
truth” and focusedmainly on reducing total body volume and treating
comorbidities.
We have proposed that changes in distribution of volume occur
due to altered capacitance of the splanchnic venous vessels, mech-
anisms under exquisite control of the autonomic nervous system (6).
This decreased venous capacitance leads to large shifts of ﬂuid from
the venous reservoir into the effective circulatory volume, increasing
ﬁlling pressures and resulting in the entity of clinical congestion
without increases in total body salt and water. This explanation is
aligned with observations that autonomic imbalance and elevated
ﬁlling pressures become evident weeks before HHF (4,7). It also
explains ﬁndings from the ADHERE (Acute Decompensated
Heart Failure National Registry) database showing that approxi-
mately half of patients hospitalized with HF are discharged with
little or no reduction in weight (8), likely a consequence of clinical
strategies that result in relief of congestion without removal of total
body salt and water. Although Dr. Gheorghiade et al. (5) have
previously entertained the concept of redistribution, they attributed
this largely to increased vascular resistance and changes in arterial
compliance. However, changes in vascular stiffness account for
only trivial changes in distribution of volume and do not adequately
explain congestion without weight gain (6).
The implications of these disparate mechanisms (weight gain vs.
redistribution) are profound. When signiﬁcant salt and water accu-
mulation does occur, therapeutic approaches targeting volume
removal seem reasonable. However, for the majority of patients in
whomweight gain does not precedeHHF, therapies aimed at volume
removal will lead to intravascular volume depletion, causing activa-
tion of the renin-angiotensin system and worsening renal function,
resulting in iatrogenically induced cardiorenal syndrome. The results
of the recent CARRESS (CARdiorenal REScue Study in Acute
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166Decompensated Heart Failure) trial highlight the high post-
discharge morbidity and mortality (w50% to 60% at 60 days) in
patients with cardiorenal syndrome who have undergone aggressive
volume removal by either diuretics or ultraﬁltration (9). We propose
that rather than targeting volume removal to treat HHF, a more
rational approachwould be to assess the relative degrees of excess total
body salt and water versus redistribution of existing volume, and to
direct therapy towards the underlying cause of the congestion.*Mark E. Dunlap, MD
Paul A. Sobotka, MD
*MetroHealth Campus of Case Western Reserve University
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Congestion, caused by elevated ventricular ﬁlling pressures, is
the primary cause of most admissions and re-admissions for heart
failure (HF). Congestion can develop rapidly with minimal warning
signs or preceding weight gain, perhaps due to a mismatch between
acute changes in afterload and/or ventricular compliance. More
commonly, congestion occurs as a gradual, insidious process as
a result of a number of cardiac and noncardiac processes, including
progression of HF (2).Dunlap and Sobotka highlight the subset of patients who may
not experience signiﬁcant weight gain before admission. Even
subtle changes in weight post-discharge are strong predictors of
re-hospitalization, with a speciﬁcity approaching 90% (3). Thus,
large perturbations in body weight over a matter of days are strongly
indicative of impending necessity for HF hospitalization. Weight
gain may not precede all admissions (poor sensitivity), but alter-
native mechanisms of congestion are difﬁcult to measure based on
available modalities and may not relate to clinical outcomes. In
2013, measurement of daily weights, albeit crude, remains one of
the most feasible approaches to outpatient monitoring of conges-
tion in terms of costs, patient accessibility, and portability of
information. Emerging technologies may help boost our ability to
detect congestion at an early pre-admission stage.
Aggressive decongestion, via primarily diuresis, remains a major
treatment modality in patients hospitalized for HF. The majority of
patients experience early dyspnea relief with the use of standard
diuretic regimens, suggesting that volume overload underlies their
symptomatic presentation (4). Hemoconcentration, even in the face
of inpatient worsening renal function, has been associated with
improved mortality (5). Inpatient weight loss and net ﬂuid loss
are associated with improved clinical outcomes at 60 days post-
discharge (6). Despite the focus on aggressive decongestion, 40%
to 50% of patients do not experience signiﬁcant weight loss during
hospitalization. This may reﬂect inadequate decongestion. Optimal
ﬂuid removal strategies and duration of and intensity of inpatient
therapy are topics that require further investigation. Although
volume re-distribution over a short period of time may result in
congestion, gradual ﬂuid overload appears to be the major driver of
subsequent events. As such, monitoring and therapeutic interven-
tions targeting ﬂuid overload may be necessary to reduce hospi-
talizations and re-hospitalizations.Muthiah Vaduganathan, MD, MPH
Gregg C. Fonarow, MD
Robert O. Bonow, MD, MS
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